The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications
Andrea K Viecelli, Elaine Pascoe, Kevan R Polkinghorne, Carmel Hawley, Peta-Anne Paul-Brent, Sunil V Badve, Alan Cass, Stephane Heritier, Peter G Kerr, Trevor A Mori, Amanda Robertson, Hooi L Seong, Ashley B Irish
BMC Nephrology | BMC | Published : 2015
Awarded by Australian & New Zealand Clinical Trials Register
The study is funded by a National Health and Medical Research Council (NHMRC) Project Grant and registered with the Australian & New Zealand Clinical Trials Register (ACTRN12607000569404). The trial is supported by unrestricted grants provided by Abbott Products Operations AG and Amgen Australia Pty Ltd. The authors gratefully acknowledge the contributions of all members of the FAVOURED Trial Study Group, dialysis nursing staff, trial co-ordinators, research staff and participants. The authors are grateful to Bayer Healthcare for supplying the aspirin and matched placebo and Abbott Products for supplying the Omacor capsules and matched placebo.